Lazuline Biotech
Hyderabad, India· Est.
An Indian biotech developing next-generation antibody therapeutics for oncology and immunology using advanced engineering platforms.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $15M
AI Company Overview
An Indian biotech developing next-generation antibody therapeutics for oncology and immunology using advanced engineering platforms.
OncologyImmunology
Technology Platform
Advanced antibody engineering platform focused on developing bispecific antibodies, antibody-drug conjugates, and Fc-engineered therapeutics with improved specificity and efficacy.
Opportunities
Growing global demand for biologics, cost advantages of Indian R&D, and increasing interest in bispecific antibodies and ADCs present significant growth potential.
Risk Factors
Early-stage clinical development risks, intense competition in antibody therapeutics, and potential regulatory challenges in global markets.
Competitive Landscape
Competes against global antibody leaders like Roche, Amgen, and Regeneron, but differentiates through cost-efficient R&D and focus on novel antibody formats for Asian-prevalent cancers.